查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751283

Perjeta 市场规模、份额、趋势分析报告：按产品、适应症、分销管道、地区、细分市场预测，2025 年至 2030 年

Perjeta Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibody, Generic Drug), By Indication (Early Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Perjeta 市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计到2030年全球帕妥珠单抗市场规模将达到59.3亿美元，2025年至2030年期间的复合年增长率为5.5%。

罗氏公司研发的单株抗体药物帕捷特（Perjeta，Pertuzumab）在 HER2 阳性乳癌治疗领域持续展现强劲势头，尤其在乳癌和转移性乳癌治疗中。作为联合治疗的一部分，帕捷特已证明在新辅助治疗和转移性治疗方法中均能改善疗效，巩固了其在乳癌综合治疗中的地位。该药物针对 HER2 受体以抑制癌细胞增殖的作用机制，使其成为现代肿瘤治疗方案的基石。

帕妥珠单抗通常与曲妥珠单抗和化疗合併使用，其在降低早期乳癌復发风险和延长转移性乳癌无恶化生存期期方面的疗效已得到可靠临床数据的支持。乳癌发生率持续上升，加之人们对乳癌的认识不断提高以及对早期诊断的重视，推动了对帕妥珠单抗等有效生物製药的需求不断增长。

医院药房仍然是帕妥珠单抗（Perjeta）分销的核心，尤其是在治疗早期，需要医生监督和输液基础设施。随着病人历程治疗过程的进展，专科药房正在扩大其作用，为癌症患者提供客製化服务，包括输液协调、个人化护理管理和依从性支援。这些药房正在帮助接受复杂生物製药治疗的患者获得持续的照护。

目前，帕妥珠单抗（Perjeta）是一种品牌药，但未来学名药和生物相似药的推出可能会显着改变市场格局。更具成本效益的替代品的出现将提高药物的可近性，并减轻长期癌症治疗的经济负担。这将产生重大影响，尤其是在新兴市场以及面临平衡创新与可负担性压力的医疗保健体系中。

与其他生物製药一样，供应链效率和低温运输物流对于维持药品品质和供应仍然至关重要。专科药局和线上药局日益增长的作用，加上数位医疗和病患管理平台的进步，为克服这些挑战并改善整体病患体验提供了机会。

「对帕妥珠单抗（Perjeta）等先进疗法的需求反映了肿瘤学领域向精准医疗的广泛转变。乳癌是全球最常见的癌症之一，对有针对性、有效的治疗方案的需求从未如此强烈。像罗氏製​​药这样的公司持续创新，以及我们医院和药房网络的战略伙伴关係关係，将是这一需求并改善全球患者治疗的关键。

Perjeta 市场报告亮点

  • 从产品来看，单株抗体领域预计将在2024年占据市场主导地位，巩固其作为乳癌治疗首选方案的地位。帕妥珠单抗是一种标靶单株抗体药物，已证明对HER2阳性乳癌具有高度特异性和有效性，使其成为该领域的主要药物类别。
  • 根据适应症，转移性乳癌在 2024 年占据了 Perjeta 市场的主导地位。该适应症正在推动对 Perjeta 的需求，因为它已被证明可以延长转移性 HER2 阳性乳癌的无恶化生存期和整体存活期。
  • 从分销管道来看，医院药房在 2024 年成为主要分销管道。由于需要静脉注射和密切的医疗监督，医院药局是 Perjeta 的主要分销管道。
  • 北美凭藉其发达的医疗基础设施、对帕妥珠单抗的高度认知以及先进的治疗方案，推动着帕妥珠单抗市场的发展。该地区对研发和创新的重视也进一步推动了市场的成长。
  • 参与 Perjeta 市场的公司包括 F. Hoffmann-La Roche Ltd、Ambrx Biopharma、Charisma Therapeutics 和 Byondis。

目录

第一章调查方法与范围

第二章执行摘要

第三章 Perjeta 市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 Perjeta 市场：产品业务分析

  • 2024年及2030年的产品市场占有率
  • 产品细分仪表板
  • 市场规模、预测与趋势分析（按产品，2018-2030 年）
  • 单株抗体
  • 学名药

第五章 PERJETA 市场指标业务分析

  • 2024年及2030年指示市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 早期乳癌
  • 转移性乳癌

第六章 Perjeta 市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 专业药房
  • 其他药局

第七章 Perjeta 市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • F. Hoffmann-La Roche Ltd
    • Ambrx Biopharma
    • Carisma Therapeutics
    • Byondis
Product Code: GVR-4-68040-590-2

Perjeta Market Growth & Trends:

The global perjeta market is anticipated to reach USD 5.93 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Perjeta (pertuzumab), a monoclonal antibody developed by F. Hoffmann-La Roche Ltd, continues to show strong momentum in the treatment of HER2-positive breast cancer, particularly in early-stage and metastatic settings. As part of combination therapies, Perjeta has demonstrated improved outcomes in both neoadjuvant and metastatic treatment regimens, solidifying its role in comprehensive breast cancer care. The drug's mechanism of action-targeting the HER2 receptor to inhibit cancer cell growth-has made it a cornerstone in modern oncology protocols.

Perjeta is commonly used in conjunction with trastuzumab and chemotherapy, and its efficacy in reducing the risk of disease recurrence in early breast cancer, as well as extending progression-free survival in metastatic cases, has been backed by robust clinical data. The continued rise in breast cancer incidence, along with growing awareness and early diagnosis initiatives, is driving increased demand for effective biologic therapies such as Perjeta.

Hospital pharmacies remain central to Perjeta's distribution, particularly during the initial phases of treatment, where medical supervision and infusion infrastructure are necessary. As patients progress through their treatment journey, specialty pharmacies play a growing role by offering services tailored to oncology patients, including infusion coordination, personalized care management, and adherence support. These pharmacies help ensure that patients undergoing complex biologic therapies maintain consistent access to treatment.

Although Perjeta is currently a branded therapy, the future introduction of a generic or biosimilar version could significantly reshape the market. The availability of more cost-effective alternatives would enhance accessibility and relieve some of the financial burden associated with long-term cancer treatment. This would be particularly impactful in emerging markets and health systems under pressure to balance innovation with affordability.

As with other biologic therapies, supply chain efficiency and cold chain logistics remain critical to maintaining drug quality and availability. The growing role of specialty and online pharmacies, combined with advancements in digital health and patient management platforms, offers opportunities to overcome these challenges and improve the overall patient experience.

The demand for advanced therapies like Perjeta reflects a broader shift toward precision medicine in oncology. With breast cancer remaining one of the most prevalent cancers worldwide, the need for targeted, effective treatment options is stronger than ever. Continued innovation by companies like F. Hoffmann-La Roche Ltd, along with strategic partnerships across hospital and pharmacy networks, will be key in meeting this demand and improving outcomes for breast cancer patients globally.

Perjeta Market Report Highlights:

  • Based on product, the monoclonal antibody segment dominated the market in 2024, solidifying its position as the preferred treatment option for breast cancer management. Perjeta is a targeted monoclonal antibody therapy, offering high specificity and effectiveness against HER2-positive breast cancer, making it the dominant drug class in this market segment.
  • Based on indication, metastatic breast cancer segment dominated the Perjeta market in 2024. Its proven ability to extend progression-free and overall survival in metastatic HER2-positive breast cancer makes this indication the primary driver of Perjeta's demand.
  • Based on distribution channel, hsopital pharmacies emerged as the dominant distribution channel in 2024. Due to the need for intravenous administration and close medical supervision, hospital pharmacies are the main distribution channel for Perjeta.
  • North America led the Perjeta market, attributed to factors such as a well-established healthcare infrastructure, high awareness of about disease, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
  • Companies operating in the Perjeta market include F. Hoffmann-La Roche Ltd, Ambrx Biopharma, Carisma Therapeutics, and Byondis.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Perjeta Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
      • 3.3.3.1. Phase 1
      • 3.3.3.2. Phase 2
      • 3.3.3.3. Phase 3
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Perjeta Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibody
    • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
  • 4.5. Generic Drug
    • 4.5.1. Generic Drug Market, 2018 - 2030 (USD Million)

Chapter 5. Perjeta Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Early Breast Cancer
    • 5.4.1. Early Breast Cancer Market, 2018 - 2030 (USD Million)
  • 5.5. Metastatic Breast Cancer
    • 5.5.1. Metastatic Breast Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Perjeta Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Perjeta Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Perjeta Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Perjeta Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Ambrx Biopharma
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Carisma Therapeutics
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Byondis
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Perjeta market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Global Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 9 North America Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 10 North America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 12 U.S. Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 13 U.S. Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 15 Canada Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Canada Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 18 Mexico Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Mexico Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 22 Europe Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Europe Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 25 UK Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 26 UK Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 28 Germany Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Germany Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 France Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 31 France Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 32 France Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 34 Italy Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Italy Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 37 Spain Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Spain Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 40 Norway Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 41 Norway Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Denmark Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Denmark Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Sweden Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 46 Sweden Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 53 Japan Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Japan Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 China Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 56 China Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 57 China Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 India Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 59 India Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 60 India Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 62 Australia Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 63 Australia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 65 South Korea Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 66 South Korea Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 68 Thailand Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 69 Thailand Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 72 Latin America Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 73 Latin America Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 75 Brazil Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 76 Brazil Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 78 Argentina Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 79 Argentina Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Perjeta market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 85 South Africa Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 86 South Africa Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 91 UAE Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 92 UAE Perjeta market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Perjeta market, by product, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Perjeta market, by indication, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Perjeta market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Perjeta market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Perjeta market dynamics
  • Fig. 12 Perjeta market: Porter's five forces analysis
  • Fig. 13 Perjeta market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Monoclonal antibody market, 2018 - 2030 (USD Million)
  • Fig. 16 Generic drug market, 2018 - 2030 (USD Million)
  • Fig. 17 Indication market, 2018 - 2030 (USD Million)
  • Fig. 18 Early breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 19 Metastatic breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 20 Distribution channel market, 2018 - 2030 (USD Million)
  • Fig. 21 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 23 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Perjeta market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Perjeta market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis, 2024
  • Fig. 79 Strategic framework